Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 4/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8259429 | 0.94 | ACE (0.37) | EPHX1PARP1KDM4EACEREN | |
| SCHEMBL12205476 | 0.94 | ACE (0.37) | EPHX1PARP1KDM4EACEREN | |
| SCHEMBL9963377 | 0.94 | ACE (0.37) | EPHX1PARP1KDM4EACEREN | |
| SCHEMBL17427852 | 0.86 | EPHX1 (0.36) | EPHX1PARP1KMT2A | |
| SCHEMBL17083297 | 0.86 | EPHX1 (0.36) | EPHX1PARP1KMT2A | |
| SCHEMBL18574581 | 0.86 | EPHX1 (0.36) | EPHX1PARP1KMT2A | |
| SCHEMBL16388299 | 0.82 | PARP1 (0.36) | PARP1KDM4EACEREN | |
| SCHEMBL584218 | 0.82 | ACE (0.44) | KDM4EACEREN | |
| SCHEMBL584217 | 0.82 | ACE (0.44) | KDM4EACEREN | |
| SCHEMBL26723935 | 0.82 | PARP1 (0.36) | PARP1KDM4EACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113416229-B | Cytotoxic and antimitotic compounds and methods of use thereof | 酵活英属哥伦比亚有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023164246-A1 | URACIL DERIVATIVES FOR STIMULATING READ-THROUGH OF PREMATURE TERMINATION CODONS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11529338-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2020-06-18 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9663533-B2 | Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-05-30 | — | — | US | disclosed |
| EP-3087091-A1 | VAR2CSA-DRUG CONJUGATES | Zymeworks Inc. (CA) | 2016-11-02 | — | — | EP | disclosed |
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2015095952-A1 | VAR2CSA-DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| EP-2167492-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | Hanmi Pharm. Co., Ltd. (KR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008150118-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | EPHX1 3588/4885PARP1 1479/4885PARP2 2532/4885 |
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | BRD4, BET1, BRD3 | EPHX1 1303/4885PARP1 92/4885PARP2 227/4885 |
| US-11529338-B2 | Compositions and methods for treating cancer | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | EPHX1 2009/4885PARP1 3274/4885PARP2 2272/4885 |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | EPHX1 2009/4885PARP1 3274/4885PARP2 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.